SHANGHAI, Oct. 17 /PRNewswire-Asia/ -- At the end of 2009, the vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech Co., Ltd. successfully landed on the Nasdaq, then Simcere, a pharmaceutical company based in Jiangsu Province, listed on the NYSE, announced a 50.8% stake in Ealong Biotech and took control of the latter, and finally Novartis, the world-famous pharmaceutical company headquartered in Switzerland, acquired an 85.0% equity in Tianyuan Bio-Pharmaceutical, a vaccine producer, for RMB850M. These deals indicate that the investors and foreign pharmaceutical giants have not slowed down their pace to enter China's vaccine market, even in the face of this economic recession.
Hosted by Global Leaders Institute, world vaccine industry leaders convened at VacChina 2010 on Sept 15 and 16 in Shanghai. The two-day executive summit featured over 30 speakers and attendances from top executives including Junfang Gao, GM of Changchun Changsheng Life Science and An Kang, Chairman of the Board from Hualan Bio to share views on the latest China vaccine industry regulatory environment, research capabilities, market trends, and status of technology applications etc. Well attended by over 200 attendees from vaccine producers home and abroad including 6 main institutes of biological products in China and top China vaccine manufacturers like Zhejiang Tianyuan, Chengda Bio, Shanghai United Cell, Wison Bio, Walvax, Tasly and Innovax gathered under the same roof to look for partnering opportunities, VacChina 2010 was undoubtedly the most high end vaccine meeting held in China this year. Besides, thanks to over 20 corporate sponsors showcasing their state of the art vaccine R&D technologies at the event, VacChina 2010 is also a premier platform for various technology providers presenting their latest advancements in vaccine bioreactor, cell